Antengene, a one-year old Shanghai start-up, has in-licensed China and East Asian rights to a Celgene cancer candidate. Celgene’s TORC1/2 inhibitor is currently in several US Phase I trials in combination with other drugs as a treatment for various cancers. The Founder and Chairman of Antengene, Jay Mei, PhD, previously worked for Celgene and spearheaded China trials of Celgene’s Revlimid, the thalidomide-based treatment for multiple myeloma. The agreement was called a strategic partnership, implying Antengene will license more Celgene drugs in the future.
